Acton, D. S., Velthuyzen, D., Lips, C. J., and Hoppner, J.W. (2000). Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 19, 3121-3125.
Airaksinen, M. S., Titievsky, A., and Saarma, M. (1999). GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 13, 313-325.
Alberti, L., Borrello, M. G., Ghizzoni, S., Torriti, F., Rizzetti, M. G., and Pierotti, M. A. (1998). Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 17, 1079-1087.
Anders, J., Kjar, S., and Ibanez, C. F. (2001). Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem 276, 35808-35817.
Angrist, M., Bolk, S., Thiel, B., Puffenberger, E. G., Hofstra, R. M., Buys, C. H., Cass, D. T., and Chakravarti, A. (1995). Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 4, 821-830.
Arighi, E., Alberti, L., Torriti, F., Ghizzoni, S., Rizzetti, M. G., Pelicci, G., Pasini, B., Bongarzone, I., Piutti, C., Pierotti, M. A., and Borrello, M. G. (1997). Identification of Shc docking site on Ret tyrosine kinase. Oncogene 14, 773-782.
Asai, N., Murakami, H., Iwashita, T., and Takahashi, M. (1996). A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. J Biol Chem 271, 17644-17649.
Attie, T., Pelet, A., Edery, P., Eng, C., Mulligan, L. M., Amiel, J., Boutrand, L., Beldjord, C., Nihoul-Fekete, C., Munnich, A., and et al. (1995). Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Hum Mol Genet 4, 1381-1386.
Attie-Bitach, T., Abitbol, M., Gerard, M., Delezoide, A. L., Auge, J., Pelet, A., Amiel, J., Pachnis, V., Munnich, A., Lyonnet, S., and Vekemans, M. (1998). Expression of the RET proto-oncogene in human embryos. Am J Med Genet 80, 481-486.
Auricchio, A., Griseri, P., Carpentieri, M. L., Betsos, N., Staiano, A., Tozzi, A., Priolo, M., Thompson, H., Bocciardi, R., Romeo, G., et al. (1999). Double heterozygosity for a RET substitution interfering with splicing and an EDNRB missense mutation in Hirschsprung disease. Am J Hum Genet 64, 1216-1221.
Badner, J. A., Sieber, W. K., Garver, K. L., and Chakravarti, A. (1990). A genetic study of Hirschsprung disease. Am J Hum Genet 46, 568-580.
Baloh, R. H., Enomoto, H., Johnson, E. M., Jr., and Milbrandt, J. (2000a). The GDNF family ligands and receptors - implications for neural development. Curr Opin Neurobiol 10, 103-110.
Baloh, R. H., Tansey, M. G., Johnson, E. M., Jr., and Milbrandt, J. (2000b). Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists. J Biol Chem 275, 3412-3420.
Baloh, R. H., Tansey, M. G., Lampe, P. A., Fahrner, T. J., Enomoto, H., Simburger, K. S., Leitner, M. L., Araki, T., Johnson, E. M., Jr., and Milbrandt, J. (1998). Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21, 1291-1302.
Barbot, N., Calmettes, C., Schuffenecker, I., Saint-Andre, J. P., Franc, B., Rohmer, V., Jallet, P., and Bigorgne, J. C. (1994). Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J Clin Endocrinol Metab 78, 114-120.
Berndt, I., Reuter, M., Saller, B., Frank-Raue, K., Groth, P., Grussendorf, M., Raue, F., Ritter, M. M., and Hoppner, W. (1998). A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83, 770-774.
Besset, V., Scott, R. P., and Ibanez, C. F. (2000). Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 275, 39159-39166.
Bisgrove, B. W., Raible, D. W., Walter, V., Eisen, J. S., and Grunwald, D. J. (1997). Expression of c-ret in the zebrafish embry potential roles in motoneuronal development. J Neurobiol 33, 749-768.
Block, M. A., Jackson, C. E., Greenawald, K. A., Yott, J. B., and Tashjian, A. H., Jr. (1980). Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Treatment implications. Arch Surg 115, 142-148.
Boccia, L. M., Green, J. S., Joyce, C., Eng, C., Taylor, S. A., and Mulligan, L. M. (1997). Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 51, 81-85.
Bocciardi, R., Mograbi, B., Pasini, B., Borrello, M. G., Pierotti, M. A., Bourget, I., Fischer, S., Romeo, G., and Rossi, B. (1997). The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15, 2257-2265.
Bolino, A., Schuffenecker, I., Luo, Y., Seri, M., Silengo, M., Tocco, T., Chabrier, G., Houdent, C., Murat, A., Schlumberger, M., and et al. (1995). RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10, 2415-2419.
Bolk, S. Angrist, M., Fornage, M., Olson, J.M., Hofstra, R., Buys, C. and Chakravarti, A. (2002).Splitting a multigenic disease: segregation at three loci explains the familial and population risk in Hirschsprung disease. Nat Genet, - under review
Bolk, S., Pelet, A., Hofstra, R. M., Angrist, M., Salomon, R., Croaker, D., Buys, C. H., Lyonnet, S., and Chakravarti, A. (2000). A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus. Proc Natl Acad Sci U S A 97, 268-273.
Bongarzone, I., Pierotti, M. A., Monzini, N., Mondellini, P., Manenti, G., Donghi, R., Pilotti, S., Grieco, M., Santoro, M., Fusco, A., and et al. (1989). High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4, 1457-1462.
Bordeaux, M. C., Forcet, C., Granger, L., Corset, V., Bidaud, C., Billaud, M., Bredesen, D. E., Edery, P., and Mehlen, P. (2000). The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. Embo J 19, 4056-4063.
Borrello, M. G., Alberti, L., Arighi, E., Bongarzone, I., Battistini, C., Bardelli, A., Pasini, B., Piutti, C., Rizzetti, M. G., Mondellini, P., et al. (1996). The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 16, 2151-2163.
Borrello, M. G., Smith, D. P., Pasini, B., Bongarzone, I., Greco, A., Lorenzo, M. J., Arighi, E., Miranda, C., Eng, C., Alberti, L., and et al. (1995). RET activation by germline MEN2A and MEN2B mutations. Oncogene 11, 2419-2427.
Botchkareva, N. V., Botchkarev, V. A., Welker, P., Airaksinen, M., Roth, W., Suvanto, P., Muller-Rover, S., Hadshiew, I. M., Peters, C., and Paus, R. (2000). New roles for glial cell line-derived neurotrophic factor and neurturin: involvement in hair cycle control. Am J Pathol 156, 1041-1053.
Bourdelat, D., Vrsansky, P., Pages, R., and Duhamel, B. (1997). Duhamel operation 40 years after: a multicentric study. Eur J Pediatr Surg 7, 70-76.
Bourne, H. R. (1995). Signal transduction. Team blue sees red. Nature 376, 727-729.
Brandi, M. L., Gagel, R. F., Angeli, A., Bilezikian, J. P., Beck-Peccoz, P., Bordi, C., Conte-Devolx, B., Falchetti, A., Gheri, R. G., Libroia, A., et al. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86, 5658-5671.
Brown, D. A., and London, E. (1998). Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14, 111-136.
Buj-Bello, A., Adu, J., Pinon, L. G., Horton, A., Thompson, J., Rosenthal, A., Chinchetru, M., Buchman, V. L., and Davies, A. M. (1997). Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. Nature 387, 721-724.
Burzynski GM, Nolte IM, Osinga J, Ceccherini I, Twigt B, Maas S, Brooks A, Verheij J, Plaza Menacho I, Buys CH, Hofstra RM. Localizing a putative mutation as the major contributor to the development of sporadic Hirschsprung disease to the RET genomic sequence between the promoter region and exon 2. Eur J Hum Genet. 2004 Aug;12(8):604-12.
Cacalano, G., Farinas, I., Wang, L. C., Hagler, K., Forgie, A., Moore, M., Armanini, M., Phillips, H., Ryan, A. M., Reichardt, L. F. (1998). GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 21, 53-62.
Carlomagno, F., Salvatore, G., Cirafici, A. M., De Vita, G., Melillo, R. M., de Franciscis, V., Billaud, M., Fusco, A., and Santoro, M. (1997). The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57, 391-395.
Carrasquillo, M., McCallion, A. S., Puffenberger, E. G., Kashuk, C. S., Nouri, N., and Chakravarti, A. (2002). Genome-wide association study identifies multiple genes in Mennonite Hirschsprung disease. Nat Genet Submitted.
Chakravarti, A. and Lyonnet, S. (2000). Hirschsprung Disease. In, The metabolic and molecular bases of inherited disease. Scriver, Beaudet, Valle and Sly; 8th edition, McGraw-Hill, New York.
Chappuis-Flament, S., Pasini, A., De Vita, G., Segouffin-Cariou, C., Fusco, A., Attie, T., Lenoir, G. M., Santoro, M., and Billaud, M. (1998). Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17, 2851-2861.
Chiariello, M., Visconti, R., Carlomagno, F., Melillo, R. M., Bucci, C., de Franciscis, V., Fox, G. M., Jing, S., Coso, O. A., Gutkind, J. S. (1998). Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2- terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16, 2435-2445.
Cik, M., Masure, S., Lesage, A. S., Van Der Linden, I., Van Gompel, P., Pangalos, M. N., Gordon, R. D., and Leysen, J. E. (2000). Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2. Influence of cRET and cooperative interactions. J Biol Chem 275, 27505-27512.
Colucci-D'Amato, G. L., D'Alessio, A., Califano, D., Cali, G., Rizzo, C., Nitsch, L., Santelli, G., and de Franciscis, V. (2000). Abrogation of nerve growth factor-induced terminal differentiation by ret oncogene involves perturbation of nuclear translocation of ERK. J Biol Chem 275, 19306-19314.
Coventry, S., Yost, C., Palmiter, R. D., and Kapur, R. P. (1994). Migration of ganglion cell precursors in the ileoceca of normal and lethal spotted embryos, a murine model for Hirschsprung disease. Lab Invest 71, 82-93.
de Graaff, E., Srinivas, S., Kilkenny, C., D'Agati, V., Mankoo, B. S., Costantini, F., and Pachnis, V. (2001). Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15, 2433-2444.
De Vita, G., Melillo, R. M., Carlomagno, F., Visconti, R., Castellone, M. D., Bellacosa, A., Billaud, M., Fusco, A., Tsichlis, P. N., and Santoro, M. (2000). Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 60, 3727-3731.
Decker, R. A., and Peacock, M. L. (1998). Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg 33, 207-214.
Decker, R. A., Peacock, M. L., and Watson, P. (1998). Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 7, 129-134.
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., and Wells, S. A., Jr. (1993). Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2, 851-856.
Dralle, H., Damm, I., Scheumann, G. F., Kotzerke, J., Kupsch, E., Geerlings, H., and Pichlmayr, R. (1994). Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24, 112-121.
Durbec, P., Marcos-Gutierrez, C. V., Kilkenny, C., Grigoriou, M., Wartiowaara, K., Suvanto, P., Smith, D., Ponder, B., Costantini, F., Saarma, M., and et al. (1996a). GDNF signalling through the Ret receptor tyrosine kinase. Nature 381, 789-793.
Durbec, P. L., Larsson-Blomberg, L. B., Schuchardt, A., Costantini, F., and Pachnis, V. (1996b). Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development 122, 349-358.
Durick, K., Gill, G. N., and Taylor, S. S. (1998). Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol 18, 2298-2308.
Durick, K., Wu, R. Y., Gill, G. N., and Taylor, S. S. (1996). Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. J Biol Chem 271, 12691-12694.
Easton, D. F., Ponder, M. A., Cummings, T., Gagel, R. F., Hansen, H. H., Reichlin, S., Tashjian, A. H., Jr., Telenius-Berg, M., and Ponder, B. A. (1989). The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 44, 208-215.
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul-Fekete, C., Ponder, B. A., and Munnich, A. (1994). Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367, 378-380.
Eigenbrot, C., and Gerber, N. (1997). X-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and implications for receptor binding. Nat Struct Biol 4, 435-438.
Eketjall, S., Fainzilber, M., Murray-Rust, J., and Ibanez, C. F. (1999). Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. Embo J 18, 5901-5910.
Emery, J. L., Finch, E., and Lister, J. (1967). Use of circumferential tangential cryostat sections of the intestine in the diagnosis of Hirschsprung's disease. J Clin Pathol 20, 263-266.
Eng, C. (1999). RET proto-oncogene in the development of human cancer. J Clin Oncol 17, 380-393.
Eng, C., Clayton, D., Schuffenecker, I., Lenoir, G., Cote, G., Gagel, R. F., van Amstel, H. K., Lips, C. J., Nishisho, I., Takai, S. I., et al. (1996a). The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276, 1575-1579.
Eng, C., and Mulligan, L. M. (1997). Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease. Hum Mutat 9, 97-109.
Eng, C., Mulligan, L. M., Healey, C. S., Houghton, C., Frilling, A., Raue, F., Thomas, G. A., and Ponder, B. A. (1996b). Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56, 2167-2170.
Eng, C., Mulligan, L. M., Smith, D. P., Healey, C. S., Frilling, A., Raue, F., Neumann, H. P., Ponder, M. A., and Ponder, B. A. (1995a). Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43, 123-127.
Eng, C., Smith, D. P., Mulligan, L. M., Healey, C. S., Zvelebil, M. J., Stonehouse, T. J., Ponder, M. A., Jackson, C. E., Waterfield, M. D., and Ponder, B. A. (1995b). A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10, 509-513.
Eng, C., Smith, D. P., Mulligan, L. M., Nagai, M. A., Healey, C. S., Ponder, M. A., Gardner, E., Scheumann, G. F., Jackson, C. E., Tunnacliffe, A., and et al. (1994). Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3, 237-241.
Enomoto, H., Araki, T., Jackman, A., Heuckeroth, R. O., Snider, W. D., Johnson, E. M., Jr., and Milbrandt, J. (1998). GFR alpha1-deficient mice have deficits in the enteric nervous system and kidneys. Neuron 21, 317-324.
Enomoto, H., Heuckeroth, R. O., Golden, J. P., Johnson, E. M., and Milbrandt, J. (2000). Development of cranial parasympathetic ganglia requires sequential actions of GDNF and neurturin. Development 127, 4877-4889.
Farndon, J. R., Leight, G. S., Dilley, W. G., Baylin, S. B., Smallridge, R. C., Harrison, T. S., and Wells, S. A., Jr. (1986). Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73, 278-281.
Fattoruso, O., Quadro, L., Libroia, A., Verga, U., Lupoli, G., Cascone, E., and Colantuoni, V. (1998). A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat Suppl 1, S167-171.
Fewtrell, M. S., Tam, P. K., Thomson, A. H., Fitchett, M., Currie, J., Huson, S. M., and Mulligan, L. M. (1994). Hirschsprung's disease associated with a deletion of chromosome 10 (q11.2q21.2): a further link with the neurocristopathies? J Med Genet 31, 325-327.
Fink, A., Lapidot, M., and Spierer, A. (1998). Ocular manifestations in multiple endocrine neoplasia type 2b. Am J Ophthalmol 126, 305-307.
Fisher S, Grice EA, Vinton RM, Bessling SL, McCallion AS. Conservation of RET Regulatory Function from Human to Zebrafish Without Sequence Similarity.Science. 2006 Mar 23; [Epub ahead of print]
Fitze G, Schierz M, Kuhlisch E, Schreiber M, Ziegler A, Roesner D, Schackert HK. Novel intronic polymorphisms in the RET proto-oncogene and their association with Hirschsprung disease. Hum Mutat. 2003 Aug;22(2):177.
Frazer, K.A., Tao, H., Osoegawa, K., de Jong, P.J., Chen, X., Doherty, M.F. and Cox, D.R. (2004) Noncoding sequences conserved in a limited number of mammals in the SIM2 interval are frequently functional. Genome Res, 14, 367-372.
Frilling, A., Bockhorn, M., Kalinin, V., Liedke, M., Kaun, M., and Broelsch, C. E. (1997). Somatic ret proto-oncogene mutations in sporadic C-cell carcinoma of the thyroid gland. Chirurg 68, 789-793.
Geneste, O., Bidaud, C., De Vita, G., Hofstra, R. M., Tartare-Deckert, S., Buys, C. H., Lenoir, G. M., Santoro, M., and Billaud, M. (1999). Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. Hum Mol Genet 8, 1989-1999.
Gestblom, C., Sweetser, D. A., Doggett, B., and Kapur, R. P. (1999). Sympathoadrenal hyperplasia causes renal malformations in Ret (MEN2B)-transgenic mice. Am J Pathol 155, 2167-2179.
Gimm, O., Marsh, D. J., Andrew, S. D., Frilling, A., Dahia, P. L., Mulligan, L. M., Zajac, J. D., Robinson, B. G., and Eng, C. (1997). Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82, 3902-3904.
Grice, E., Rochelle, E.S., Green, E.D., Chakravarti, A., and McCallion, A.S. (2005). Evaluation of the RET regulatory landscape reveals the biological relevance of a HSCR-implicated enhancer. Human Molecular Genetics, 14 (24):3837-45.
Griseri P, Bachetti T, Puppo F, Lantieri F, Ravazzolo R, Devoto M, Ceccherini I. A common haplotype at the 5' end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression. Hum Mutat. 2005 Feb;25(2):189-95.
Golden, J. P., Baloh, R. H., Kotzbauer, P. T., Lampe, P. A., Osborne, P. A., Milbrandt, J., and Johnson, E. M., Jr. (1998). Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp Neurol 398, 139-150.
Golden, J. P., DeMaro, J. A., Osborne, P. A., Milbrandt, J., and Johnson, E. M., Jr. (1999). Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neurol 158, 504-528.
Gorlin, R. J., Sedano, H. O., Vickers, R. A., and Cervenka, J. (1968). Multiple mucosal neuromas, pheochromocytoma and medullary carcinoma of the thyroid--a syndrome. Cancer 22, 293-299.
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Porta, G., Fusco, A., and Vecchio, G. (1990). PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60, 557-563.
Guilloteau, D., Perdrisot, R., Calmettes, C., Baulieu, J. L., Lecomte, P., Kaphan, G., Milhaud, G., Besnard, J. C., Jallet, P., and Bigorgne, J. C. (1990). Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT. J Clin Endocrinol Metab 71, 1064-1067.
Hahn, M., and Bishop, J. (2001). Expression pattern of Drosophila ret suggests a common ancestral origin between the metamorphosis precursors in insect endoderm and the vertebrate enteric neurons. Proc Natl Acad Sci U S A 98, 1053-1058.
Hanks, S. K., Quinn, A. M., and Hunter, T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52.
Hansford, J. R., and Mulligan, L. M. (2000). Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37, 817-827.
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H. (2000). Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19, 4469-4475.
Hearn, C. J., Murphy, M., and Newgreen, D. (1998). GDNF and ET-3 differentially modulate the numbers of avian enteric neural crest cells and enteric neurons in vitro. Dev Biol 197, 93-105.
Hellmich, H. L., Kos, L., Cho, E. S., Mahon, K. A., and Zimmer, A. (1996). Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelial-mesenchymal interactions. Mech Dev 54, 95-105.
Henderson, C. E., Phillips, H. S., Pollock, R. A., Davies, A. M., Lemeulle, C., Armanini, M., Simmons, L., Moffet, B., Vandlen, R. A., Simpson, L. C., and et al. (1994). GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266, 1062-1064.
Hennessy, J. F., Gray, T. K., Cooper, C. W., and Ontjes, D. A. (1973). Stimulation of thyrocalcitonin secretion by pentagastrin and calcium in 2 patients with medullary carcinoma of the thyroid. J Clin Endocrinol Metab 36, 200-203.
Heuckeroth, R. O., Enomoto, H., Grider, J. R., Golden, J. P., Hanke, J. A., Jackman, A., Molliver, D. C., Bardgett, M. E., Snider, W. D., Johnson, E. M., Jr., and Milbrandt, J. (1999). Gene targeting reveals a critical role for neurturin in the development and maintenance of enteric, sensory, and parasympathetic neurons. Neuron 22, 253-263.
Heuckeroth, R. O., Lampe, P. A., Johnson, E. M., and Milbrandt, J. (1998). Neurturin and GDNF promote proliferation and survival of enteric neuron and glial progenitors in vitro. Dev Biol 200, 116-129.
Hofstra, R. M., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W., van Amstel, H. K., Romeo, G. (1994). A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375-376.
Hoppner, W., Dralle, H., and Brabant, G. (1998). Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum Mutat Suppl 1, S128-130.
Hoppner, W., and Ritter, M. M. (1997). A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6, 587-590.
Hosoda, K., Hammer, R. E., Richardson, J. A., Baynash, A. G., Cheung, J. C., Giaid, A., and Yanagisawa, M. (1994). Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79, 1267-1276.
Ito, S., Iwashita, T., Asai, N., Murakami, H., Iwata, Y., Sobue, G., and Takahashi, M. (1997). Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. Cancer Res 57, 2870-2872.
Ivanchuk, S. M., Eng, C., Cavenee, W. K., and Mulligan, L. M. (1997). The expression of RET and its multiple splice forms in developing human kidney. Oncogene 14, 1811-1818.
Ivanchuk, S. M., Myers, S. M., and Mulligan, L. M. (1998). Expression of RET 3' splicing variants during human kidney development. Oncogene 16, 991-996.
Iwashita, T., Kurokawa, K., Qiao, S., Murakami, H., Asai, N., Kawai, K., Hashimoto, M., Watanabe, T., Ichihara, M., and Takahashi, M. (2001). Functional analysis of RET with Hirschsprung mutations affecting its kinase domain. Gastroenterology 121, 24-33.
Iwashita, T., Murakami, H., Asai, N., and Takahashi, M. (1996). Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. Hum Mol Genet 5, 1577-1580.
Jhiang, S. M. (2000). The RET proto-oncogene in human cancers. Oncogene 19, 5590-5597.
Jhiang, S. M., and Mazzaferri, E. L. (1994). The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 123, 331-337.
Jing, S., Wen, D., Yu, Y., Holst, P. L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., et al. (1996). GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85, 1113-1124.
Jing, S., Yu, Y., Fang, M., Hu, Z., Holst, P. L., Boone, T., Delaney, J., Schultz, H., Zhou, R., and Fox, G. M. (1997). GFRalpha-2 and GFRalpha-3 are two new receptors for ligands of the GDNF family. J Biol Chem 272, 33111-33117.
Kashuk, C.S., Stone, A.E., Grice, E.A., Portnoy, M.E., Green, E.D., Sidow, A., Chakravarti, A. and McCallion, A.S. (2005) Phenotype:Genotype correlation in HSCR and MEN2 facilitated comparative analysis of the RET protein sequence. Proceedings of the National Academy of Science (USA) 102: 8949-8954.
Kawai, K., Iwashita, T., Murakami, H., Hiraiwa, N., Yoshiki, A., Kusakabe, M., Ono, K., Iida, K., Nakayama, A., and Takahashi, M. (2000). Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res 60, 5254-5260.
Lane, P. W. (1966). Association of megacolon with two recessive spotting genes in the mouse. J Hered 57, 29-31.
Lantieri F, Griseri P, Puppo F, Campus R, Martucciello G, Ravazzolo R, Devoto M, Ceccherini I. Haplotypes of the human RET proto-oncogene associated with Hirschsprung disease in the Italian population derive from a single ancestral combination of alleles. Ann Hum Genet. 2006 Jan;70(Pt 1):12-26.
Le Douarin, N., and Kalcheim, C. (1999). The Neural Crest. 2nd edition (Cambridge, Cambridge Univ Press).
Lindahl, M., Poteryaev, D., Yu, L., Arumae, U., Timmusk, T., Bongarzone, I., Aiello, A., Pierotti, M. A., Airaksinen, M. S., and Saarma, M. (2001). Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem 276, 9344-9351.
Lips, C. J., Landsvater, R. M., Hoppener, J. W., Geerdink, R. A., Blijham, G., van Veen, J. M., van Gils, A. P., de Wit, M. J., Zewald, R. A., Berends, M. J. (1994). Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331, 828-835.
Liu, X., Vega, Q. C., Decker, R. A., Pandey, A., Worby, C. A., and Dixon, J. E. (1996). Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 271, 5309-5312.
Lo, L., and Anderson, D. J. (1995). Postmigratory neural crest cells expressing c-RET display restricted developmental and proliferative capacities. Neuron 15, 527-539.
Loots, G.G., Locksley, R.M., Blankespoor, C.M., Wang, Z.E., Miller, W., Rubin, E.M. and Frazer, K.A. (2000) Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science, 288, 136-140.
Lorenzo, M. J., Eng, C., Mulligan, L. M., Stonehouse, T. J., Healey, C. S., Ponder, B. A., and Smith, D. P. (1995). Multiple mRNA isoforms of the human RET proto-oncogene generated by alternate splicing. Oncogene 10, 1377-1383.
Lorenzo, M. J., Gish, G. D., Houghton, C., Stonehouse, T. J., Pawson, T., Ponder, B. A., and Smith, D. P. (1997). RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene 14, 763-771.
Luo, Y., Ceccherini, I., Pasini, B., Matera, I., Bicocchi, M. P., Barone, V., Bocciardi, R., Kaariainen, H., Weber, D., Devoto, M., and et al. (1993). Close linkage with the RET protooncogene and boundaries of deletion mutations in autosomal dominant Hirschsprung disease. Hum Mol Genet 2, 1803-1808.
Luttrell, L. M., Daaka, Y., and Lefkowitz, R. J. (1999). Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol 11, 177-183.
Manié, S., Santoro, M., Fusco, A., and Billaud, M. (2001). The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 17, 580-589.
Marcos-Gutierrez, C. V., Wilson, S. W., Holder, N., and Pachnis, V. (1997). The zebrafish homologue of the ret receptor and its pattern of expression during embryogenesis. Oncogene 14, 879-889.
Marsh, D. J., Andrew, S. D., Eng, C., Learoyd, D. L., Capes, A. G., Pojer, R., Richardson, A. L., Houghton, C., Mulligan, L. M., Ponder, B. A., and Robinson, B. G. (1996). Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 56, 1241-1243.
Marsh, D. J., Robinson, B. G., Andrew, S., Richardson, A. L., Pojer, R., Schnitzler, M., Mulligan, L. M., and Hyland, V. J. (1994). A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 23, 477-479.
Martin, L. W. (1982). Total colonic aganglionosis preservation and utilization of entire colon. J Pediatr Surg 17, 635-637.
Martin, L. W., and Caudill, D. R. (1967). A method for elimination of the blind rectal pouch in the Duhamel operation for Hirschsprung's disease. Surgery 62, 951-953.
Martin, L. W., and Torres, A. M. (1985). Hirschsprung's disease. Surg Clin North Am 65, 1171-1180.
Masure, S., Cik, M., Hoefnagel, E., Nosrat, C. A., Van der Linden, I., Scott, R., Van Gompel, P., Lesage, A. S., Verhasselt, P., Ibanez, C. F., and Gordon, R. D. (2000). Mammalian GFRalpha -4, a divergent member of the GFRalpha family of coreceptors for glial cell line-derived neurotrophic factor family ligands, is a receptor for the neurotrophic factor persephin. J Biol Chem 275, 39427-39434.
McCallion, A. S., and Chakravarti, A. (2001). EDNRB/EDN3 and Hirschsprung disease type II. Pigment Cell Res 14, 161-169.
Meier-Ruge, W., Hunziker, O., Tobler, H. J., and Walliser, C. (1972). The pathophysiology of aganglionosis of the entire colon (Zuelzer-Wilson syndrome). Morphometric investigations of the extent of sacral parasympathetic innervation of the circular muscles of the aganglionic colon. Beitr Pathol 147, 228-236.
Melillo, R. M., Carlomagno, F., De Vita, G., Formisano, P., Vecchio, G., Fusco, A., Billaud, M., and Santoro, M. (2001a). The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3- kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Oncogene 20, 209-218.
Melillo, R. M., Santoro, M., Ong, S. H., Billaud, M., Fusco, A., Hadari, Y. R., Schlessinger, J., and Lax, I. (2001b). Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol 21, 4177-4187.
Mercer, E. H., Hoyle, G. W., Kapur, R. P., Brinster, R. L., and Palmiter, R. D. (1991). The dopamine beta-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 7, 703-716.
Michiels, F. M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G. M., Feunteun, J., and Billaud, M. (1997). Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci U S A 94, 3330-3335.
Milbrandt, J., de Sauvage, F. J., Fahrner, T. J., Baloh, R. H., Leitner, M. L., Tansey, M. G., Lampe, P. A., Heuckeroth, R. O., Kotzbauer, P. T., Simburger, K. S., et al. (1998). Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20, 245-253.
Milla, P. J. (1996). Intestinal motility during ontogeny and intestinal pseudo-obstruction in children. Pediatr Clin North Am 43, 511-532.
Moers, A. M., Landsvater, R. M., Schaap, C., Jansen-Schillhorn van Veen, J. M., de Valk, I. A., Blijham, G. H., Hoppener, J. W., Vroom, T. M., van Amstel, H. K., and Lips, C. J. (1996). Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101, 635-641.
Moley, J. F., and DeBenedetti, M. K. (1999). Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229, 880-887; discussion 887-888.
Moore, M. W., Klein, R. D., Farinas, I., Sauer, H., Armanini, M., Phillips, H., Reichardt, L. F., Ryan, A. M., Carver-Moore, K., and Rosenthal, A. (1996a). Renal and neuronal abnormalities in mice lacking GDNF. Nature 382, 76-79.
Moore, S. W., Albertyn, R., and Cywes, S. (1996b). Clinical outcome and long-term quality of life after surgical correction of Hirschsprung's disease. J Pediatr Surg 31, 1496-1502.
Mulligan, L. M., Eng, C., Attie, T., Lyonnet, S., Marsh, D. J., Hyland, V. J., Robinson, B. G., Frilling, A., Verellen-Dumoulin, C., Safar, A., and et al. (1994). Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 3, 2163-2167.
Mulligan, L. M., Kwok, J. B., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., and et al. (1993). Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460.
Mulligan, L. M., and Ponder, B. A. (1995). Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 80, 1989-1995.
Murakami, H., Iwashita, T., Asai, N., Shimono, Y., Iwata, Y., Kawai, K., and Takahashi, M. (1999). Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 262, 68-75.
Nakamura, T., Ishizaka, Y., Nagao, M., Hara, M., and Ishikawa, T. (1994). Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 172, 255-260.
Neilson, I. R., and Yazbeck, S. (1990). Ultrashort Hirschsprung's disease: myth or reality. J Pediatr Surg 25, 1135-1138.
Neumann, H. P., Eng, C., Mulligan, L. M., Glavac, D., Zauner, I., Ponder, B. A., Crossey, P. A., Maher, E. R., and Brauch, H. (1995). Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 274, 1149-1151.
Nihoule-Fekete, C., Ricour, C., Martelli, H., Jacob, S. L., and Pellerin, D. (1986). Total colonic aganglionosis (with or without ileal involvement): a review of 27 cases. J Pediatr Surg 21, 251-254.
Nishino, J., Mochida, K., Ohfuji, Y., Shimazaki, T., Meno, C., Ohishi, S., Matsuda, Y., Fujii, H., Saijoh, Y., and Hamada, H. (1999). GFR alpha3, a component of the artemin receptor, is required for migration and survival of the superior cervical ganglion. Neuron 23, 725-736.
Nozaki, C., Asai, N., Murakami, H., Iwashita, T., Iwata, Y., Horibe, K., Klein, R. D., Rosenthal, A., and Takahashi, M. (1998). Calcium-dependent Ret activation by GDNF and neurturin. Oncogene 16, 293-299.
Offit, K., Biesecker, B. B., and Burt, R. W. (1996). Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Onc 14, 1730-1736.
Ohiwa, M., Murakami, H., Iwashita, T., Asai, N., Iwata, Y., Imai, T., Funahashi, H., Takagi, H., and Takahashi, M. (1997). Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations. Biochem Biophys Res Commun 237, 747-751.
Olson, J. A., Jr., DeBenedetti, M. K., Baumann, D. S., and Wells, S. A., Jr. (1996). Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann Surg 223, 472-478; discussion 478-480.
Pachnis, V., Mankoo, B., and Costantini, F. (1993). Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 119, 1005-1017.
Pandey, A., Duan, H., Di Fiore, P. P., and Dixit, V. M. (1995). The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J Biol Chem 270, 21461-21463.
Pasini, A., Geneste, O., Legrand, P., Schlumberger, M., Rossel, M., Fournier, L., Rudkin, B. B., Schuffenecker, I., Lenoir, G. M., and Billaud, M. (1997). Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 15, 393-402.
Pasini, B., Borrello, M. G., Greco, A., Bongarzone, I., Luo, Y., Mondellini, P., Alberti, L., Miranda, C., Arighi, E., Bocciardi, R., and et al. (1995). Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 10, 35-40.
Pasini, B., Ceccherini, I., and Romeo, G. (1996). RET mutations in human disease. Trends Genet 12, 138-144.
Pastinen, T. and Hudson, T.J. (2004) Cis-acting regulatory variation in the human genome. Science, 306, 647-650.
Pelet, A., Geneste, O., Edery, P., Pasini, A., Chappuis, S., Atti, T., Munnich, A., Lenoir, G., Lyonnet, S., and Billaud, M. (1998). Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. J Clin Invest 101, 1415-1423.
Pellerin, D. (1992). Hirschsprung disease. Cir Pediatr 5, 57-63.
Pennacchio, L.A., Olivier, M., Hubacek, J.A., Cohen, J.C., Cox, D.R., Fruchart, J.C., Krauss, R.M. and Rubin, E.M. (2001) An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 294, 169-173.
Phay, J. E., Moley, J. F., and Lairmore, T. C. (2000). Multiple endocrine neoplasias. Semin Surg Oncol 18, 324-332.
Pichel, J. G., Shen, L., Sheng, H. Z., Granholm, A. C., Drago, J., Grinberg, A., Lee, E. J., Huang, S. P., Saarma, M., Hoffer, B. J., et al. (1996a). Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382, 73-76.
Pichel, J. G., Shen, L., Sheng, H. Z., Granholm, A. C., Drago, J., Grinberg, A., Lee, E. J., Huang, S. P., Saarma, M., Hoffer, B. J., et al. (1996b). GDNF is required for kidney development and enteric innervation. Cold Spring Harb Symp Quant Biol 61, 445-457.
Pigny, P., Bauters, C., Wemeau, J. L., Houcke, M. L., Crepin, M., Caron, P., Giraud, S., Calender, A., Buisine, M. P., Kerckaert, J. P., and Porchet, N. (1999). A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84, 1700-1704.
Ponder, B. A. (1999). The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59, 1736s-1741s; discussion 1742s.
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., and Ullrich, A. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888.
Puffenberger, E. G., Kauffman, E. R., Bolk, S., Matise, T. C., Washington, S. S., Angrist, M., Weissenbach, J., Garver, K. L., Mascari, M., Ladda, R., and et al. (1994). Identity-by-descent and association mapping of a recessive gene for Hirschsprung disease on human chromosome 13q22. Hum Mol Genet 3, 1217-1225.
Rabes, H. M., Demidchik, E. P., Sidorow, J. D., Lengfelder, E., Beimfohr, C., Hoelzel, D., and Klugbauer, S. (2000). Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 6, 1093-1103.
Reding, R., de Ville de Goyet, J., Gosseye, S., Clapuyt, P., Sokal, E., Buts, J. P., Gibbs, P., and Otte, J. B. (1997). Hirschsprung's disease: a 20-year experience. J Pediatr Surg 32, 1221-1225.
Rescorla, F. J., Morrison, A. M., Engles, D., West, K. W., and Grosfeld, J. L. (1992). Hirschsprung's disease. Evaluation of mortality and long-term function in 260 cases. Arch Surg 127, 934-941; discussion 941-932.
Reynolds, L., Jones, K., Winton, D. J., Cranston, A., Houghton, C., Howard, L., Ponder, B. A., and Smith, D. P. (2001). C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene 20, 3986-3994.
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kaariainen, H., and et al. (1994). Point mutations affecting the tyrosine kinase domain of the RET proto- oncogene in Hirschsprung's disease. Nature 367, 377-378.
Rossel, M., Pasini, A., Chappuis, S., Geneste, O., Fournier, L., Schuffenecker, I., Takahashi, M., van Grunsven, L. A., Urdiales, J. L., Rudkin, B. B., et al. (1997). Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene 14, 265-275.
Rossel, M., Schuffenecker, I., Schlumberger, M., Bonnardel, C., Modigliani, E., Gardet, P., Navarro, J., Luo, Y., Romeo, G., Lenoir, G., and et al. (1995). Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet 95, 403-406.
Rossi, J., Luukko, K., Poteryaev, D., Laurikainen, A., Sun, Y. F., Laakso, T., Eerikainen, S., Tuominen, R., Lakso, M., Rauvala, H., et al. (1999). Retarded growth and deficits in the enteric and parasympathetic nervous system in mice lacking GFR alpha2, a functional neurturin receptor. Neuron 22, 243-252.
Rossi, J., Tomac, A., Saarma, M., and Airaksinen, M. S. (2000). Distinct roles for GFRalpha1 and GFRalpha2 signalling in different cranial parasympathetic ganglia in vivo. Eur J Neurosci 12, 3944-3952.
Saarma, M. (2000). GDNF - a stranger in the TGF-beta superfamily? Eur J Biochem 267, 6968-6971.
Sanchez, M. P., Silos-Santiago, I., Frisen, J., He, B., Lira, S. A., and Barbacid, M. (1996). Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382, 70-73.
Santoro, M., Carlomagno, F., Melillo, R. M., Billaud, M., Vecchio, G., and Fusco, A. (1999). Molecular mechanisms of RET activation in human neoplasia. J Endocrinol Invest 22, 811-819.
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., and et al. (1995). Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381-383.
Saxen, L., and Sariola, H. (1987). Early organogenesis of the kidney. Pediatr Nephrol 1, 385-392.
Schimke, R. N. (1984). Genetic aspects of multiple endocrine neoplasia. Annu Rev Med 35, 25-31.
Schimke, R. N., Hartman, W. H., Prout, T. W., and Rimoin, D. L. (1968). Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuroma. N Eng J Med 279, 1-7.
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., and Pachnis, V. (1994). Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367, 380-383.
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., and Pachnis, V. (1995a). RET-deficient mice: an animal model for Hirschsprung's disease and renal agenesis. J Intern Med 238, 327-332.
Schuchardt, A., D'Agati, V., Pachnis, V., and Costantini, F. (1996). Renal agenesis and hypodysplasia in ret-k- mutant mice result from defects in ureteric bud development. Development 122, 1919-1929.
Schuchardt, A., Srinivas, S., Pachnis, V., and Costantini, F. (1995b). Isolation and characterization of a chicken homolog of the c-ret proto-oncogene. Oncogene 10, 641-649.
Schuffenecker, I., Virally-Monod, M., Brohet, R., Goldgar, D., Conte-Devolx, B., Leclerc, L., Chabre, O., Boneu, A., Caron, J., Houdent, C., et al. (1998). Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83, 487-491.
Segouffin-Cariou, C., and Billaud, M. (2000). Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 275, 3568-3576.
Seri, M., Yin, L., Barone, V., Bolino, A., Celli, I., Bocciardi, R., Pasini, B., Ceccherini, I., Lerone, M., Kristoffersson, U., et al. (1997). Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat 9, 243-249.
Smith, D. P., Houghton, C., and Ponder, B. A. (1997). Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15, 1213-1217.
Soave, F. (1966a). Hirschsprung's disease. Technique and results of Soave's operation. Br J Surg 53, 1023-1027.
Soave, F. (1966b). A new surgical method for the treatment of Hirschsprung's disease. Khirurgiia (Mosk) 42, 60-65.
Soave, F. (1970). Hirschsprung's disease: Soave's operation. Ann Chir Infant 11, 84-88.
Soave, F. (1977). Megacolon: long-term results of surgical treatment. Prog Pediatr Surg 10, 141-149.
Soave, F. (1978). Extramucosal endorectal pull through. Curr Probl Surg 15, 77-93.
Soave, F. (1985). Endorectal pull-through: 20 years experience. Address of the guest speaker, APSA, 1984. J Pediatr Surg 20, 568-579.
Songyang, Z., Gish, G., Mbamalu, G., Pawson, T., and Cantley, L. C. (1995). A single point mutation switches the specificity of group III Src homology (SH) 2 domains to that of group I SH2 domains. J Biol Chem 270, 26029-26032.
Sproat-Emison, E.E.,* McCallion, A.S.,* Kashuk, C.S., Bush, R.T., Grice, E., Lin, S., Portnoy, M.E., NISC Comparative Sequencing Program, Cutler, D.J., Green, E.D. and Chakravarti, A. (2005) A common, sex-dependent mutation in a putative RET enhancer underlies Hirschsprung disease susceptibility. Nature, 434 (7035): 857-63. (*, Authors contributed equally).
Srinivas, S., Wu, Z., Chen, C. M., D'Agati, V., and Costantini, F. (1999). Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development. Development 126, 1375-1386.
Stone EA, Sidow A. Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity.Genome Res. 2005 Jul;15(7):978-86
Sugaya, R., Ishimaru, S., Hosoya, T., Saigo, K., and Emori, Y. (1994). A Drosophila homolog of human proto-oncogene ret transiently expressed in embryonic neuronal precursor cells including neuroblasts and CNS cells. Mech Dev 45, 139-145.
Sweetser, D. A., Froelick, G. J., Matsumoto, A. M., Kafer, K. E., Marck, B., Palmiter, R. D., and Kapur, R. P. (1999). Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice. Oncogene 18, 877-886.
Swenson, O. (1967). The pull-through operation for congenital megacolon. Rev Surg 24, 229-232.
Swenson, O. (1996). Early history of the therapy of hirschsprung disease: Facts and personal observations over 50 years. J Pediatr Surg 31, 1003.
Swenson, O., and Bill, A. (1948). Resection of rectum and rectosigmoid with preservation of sphincter for benign spastic lesions producing megacolon. Surgery 24, 212.
Takahashi, M. (2001). The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12, 361-373.
Takahashi, M., Asai, N., Iwashita, T., Isomura, T., Miyazaki, K., and Matsuyama, M. (1993). Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 8, 2925-2929.
Takahashi, M., Asai, N., Iwashita, T., Murakami, H., and Ito, S. (1998). Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations. Recent Results Cancer Res 154, 229-236.
Takahashi, M., and Cooper, G. M. (1987). ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 7, 1378-1385.
Takahashi, M., Iwashita, T., Santoro, M., Lyonnet, S., Lenoir, G. M., and Billaud, M. (1999). Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat 13, 331-336.
Takahashi, M., Ritz, J., and Cooper, G. M. (1985). Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42, 581-588.
Tansey, M. G., Baloh, R. H., Milbrandt, J., and Johnson, E. M., Jr. (2000). GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25, 611-623.
Taraviras, S., Marcos-Gutierrez, C. V., Durbec, P., Jani, H., Grigoriou, M., Sukumaran, M., Wang, L. C., Hynes, M., Raisman, G., and Pachnis, V. (1999). Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development 126, 2785-2797.
Thakker, R. V., and Ponder, B. A. (1988). Multiple endocrine neoplasia. Baillieres Clin Endocrinol Metab 2, 1031-1067.
Toogood, A. A., Eng, C., Smith, D. P., Ponder, B. A., and Shalet, S. M. (1995). No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B. Clin Endocrinol 43, 759-762.
Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A. S., Sieber, B. A., Grigoriou, M., Kilkenny, C., Salazar-Grueso, E., Pachnis, V., and Arumae, U. (1996). Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381, 785-789.
van Biesen, T., Hawes, B. E., Luttrell, D. K., Krueger, K. M., Touhara, K., Porfiri, E., Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. (1995). Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway. Nature 376, 781-784.
van Heurn, L. W., Schaap, C., Sie, G., Haagen, A. A., Gerver, W. J., Freling, G., van Amstel, H. K., and Heineman, E. (1999). Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 34, 568-571.
van Puijenbroek, A. A., van Weering, D. H., van den Brink, C. E., Bos, J. L., van der Saag, P. T., de Laat, S. W., and den Hertog, J. (1997). Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation. Oncogene 14, 1147-1157.
van Weering, D. H., and Bos, J. L. (1998). Signal transduction by the receptor tyrosine kinase Ret. Recent Results Cancer Res 154, 271-281.
van Weering, D. H., Moen, T. C., Braakman, I., Baas, P. D., and Bos, J. L. (1998). Expression of the receptor tyrosine kinase Ret on the plasma membrane is dependent on calcium. J Biol Chem 273, 12077-12081.
Vasen, H. F., van der Feltz, M., Raue, F., Kruseman, A. N., Koppeschaar, H. P., Pieters, G., Seif, F. J., Blum, W. F., and Lips, C. J. (1992). The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med 152, 1250-1252.
Webster, W. (1974). Aganglionic megacolon in piebald-lethal mice. Arch Pathol 97, 111-117.
Weinberg, A. G. (1975). Hirschsprung's disease - a pathologist's view. Perspect Pediatr Pathol 2, 207-239.
Wells, S. A., Jr., Baylin, S. B., Linehan, W. M., Farrell, R. E., Cox, E. B., and Cooper, C. W. (1978). Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 188, 139-141.
Wells, S. A., Jr., Chi, D. D., Toshima, K., Dehner, L. P., Coffin, C. M., Dowton, S. B., Ivanovich, J. L., DeBenedetti, M. K., Dilley, W. G., Moley, J. F., and et al. (1994). Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220, 237-247; discussion 247-250.
White, F. V., and Langer, J. C. (2000). Circumferential distribution of ganglion cells in the transition zone of children with Hirschsprung disease. Pediatr Dev Pathol 3, 216-222.
Whitehouse, F., and kernohan, J. (1948). Myenteric plexuses in congenital megacolon: Study of 11 cases. Arch Int Med 82, 75.
Widenfalk, J., Widmer, H. R., and Spenger, C. (1999). GDNF, RET and GFRalpha-1-3 mRNA expression in the developing human spinal cord and ganglia. Neuroreport 10, 1433-1439.
Wohllk, N., Cote, G. J., Bugalho, M. M., Ordonez, N., Evans, D. B., Goepfert, H., Khorana, S., Schultz, P., Richards, C. S., and Gagel, R. F. (1996). Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81, 3740-3745.
Yanchar, N. L., and Soucy, P. (1999). Long-term outcome after Hirschsprung's disease: patients' perspectives. J Pediatr Surg 34, 1152-1160.
Young, H. M., Ciampoli, D., Hsuan, J., and Canty, A. J. (1999). Expression of
Ret-, p75(NTR)-, Phox2a-, Phox2b-, and tyrosine hydroxylase-immunoreactivity by undifferentiated neural crest-derived cells and different classes of enteric neurons in the embryonic mouse gut. Dev Dyn 216, 137-152.
